| GR00016-A | 1459 | 1459 | CSNK2A2 | np | 1.33 | none | | no | | Wnt/beta-catenin pathway regulation | Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. | James et al. | 2009 | 19471023 | Cell line | RKO | Wnt/beta-catenin pathway reporter | Luminescence | rp | Selected genes | siRNA | Z-score | > 2 | | GR00053-A | 1459 | NM_001896 | CSNK2A2 | np | sp | Increased gamma-H2AX phosphorylation | | no | group 3 | Genome stability | A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. | Paulsen et al. | 2009 | 19647519 | Cell line | HeLa | gamma-H2AX phosphorylation and DNA content | Fluorescence | siARRAY human genome siRNA library | Genome-wide | siRNA | p-value | Complex criteria | Confidence groupings from 4 to 1 (highest level of confidence in group 4) | GR00054-A | 1459 | NM_001896 | CSNK2A2 | np | 1.054 | none | | no | | Combinatorial effect with paclitaxel | Synthetic lethal screen identification of chemosensitizer loci in cancer cells. | Whitehurst et al. | 2007 | 17429401 | Cell line | NCI-H1155 | Viability (synthetic lethal) | ATP level | # G-005000-01 | Genome-wide | siRNA | Paclitaxel/control ratio | Complex criteria | Additional information about 87 high-confidence hits | | 1459 | 1459 | CSNK2A2 | np | np | Decreased cell migration | | yes | deconvoluted validated siRNAs: 3/4 | | | | | | | | | | | | | | | | GR00056-A | 1459 | NM_001896 | CSNK2A2 | np | 1.399 | none | | no | | Melanogenesis | Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. | Ganesan et al. | 2008 | 19057677 | Cell line | MNT-1 | Melanin protein expression and viability | Absorbance and luminescence | rp | Genome-wide | siRNA | Normalized absorbance ratio | > 2 standard deviations below mean | Additional information about a secondary screen (retest to determine false-positive rate) | GR00057-A-1 | 1459 | NM_001896 | CSNK2A2 | M-004752-00 | -0.9 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 1459 | NM_001896 | CSNK2A2 | M-004752-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00095-A | 1459 | NM_001896 | CSNK2A2 | np | np | none | | | | p53 pathway components | A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Berns et al. | 2004 | 15042092 | Cell line | BJ-TERT-tsLT fibroblasts | Proliferation | Colony-forming cell assay | Nki library | Genome-wide | shRNA | np | np | | GR00098-A-1 | 1459 | ENSG00000070770 | CSNK2A2 | ENSG00000070770 | sp | Decreased cell number | | yes | G0/1 arrest, validated with resynthesized esiRNA | Cell division (1) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Cell number and DNA content | Laser scanning cytometry | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00098-A-2 | 1459 | ENSG00000070770 | CSNK2A2 | ENSG00000070770_2 | sp | G0/1 arrest | | yes | | Cell division (2) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Cell number and DNA content | Laser scanning cytometry | rp | Selected genes | esiRNA | Complex, sp | Complex criteria | | GR00098-A-3 | 1459 | ENSG00000070770 | CSNK2A2 | ENSG00000070770 | 0.3 | none | | yes | | Cell division (3) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Histone H3 phosphorylation; alpha-tubulin and pericentrin protein expression | Fluorescence | rp | Selected genes | esiRNA | Mitotic index | > | | GR00098-A-4 | 1459 | ENSG00000070770 | CSNK2A2 | ENSG00000070770 | -4 | none | | no | | Cell division (4) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Cell size (forward scatter) | Flow cytometry | rp | Selected genes | esiRNA | Cell size | > | | GR00114-A | 1459 | | CSNK2A2 | np | -1.84 | none | | | 70% | Combinatorial effect with Poly (ADP‐ribose)‐polymerase‐1 (PARP) | A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. | Turner et al. | 2008 | 18388863 | Cell line | CAL51 | Viability | Luminescence | siARRAY SMARTpool | Kinases | siRNA | Z-score | < | Growth rates (%) for vehicle-alone experiments are given in the comment field. | GR00121-A | 1459 | | CK2a2 | TRCN0000000611 | 27.66 | none | | | | Combinatorial effect with Von Hippel-Lindau (VHL) | Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. | Bommi-Reddy et al. | 2008 | 18948595 | Cell line | 786-O | Viability | Colorimetric | lentiviral library | Kinases | shRNA | Differential loss of viability (%) | > | Additional screen in RCC4 cells available | GR00123-A | 1459 | NM_001896 | CSNK2A2 | 101081, 101083, 101082 | np | none | | | | Combinatorial effect with nutlin-3 | An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors | Brummelkamp et al. | 2006 | 16474381 | Cell line | MCF-7 | Viability | Fluoresence | Nki library | Genome-wide | shRNA | log2 ratio | np | | GR00133-A-1 | 1459 | 1459 | CSNK2A2 | np | 0.141386 | none | | no | | Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) | RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. | Misselwitz et al. | 2011 | 21407211 | Cell line | HeLa | Gentamycin protection invasion assay | Fluorescence | Druggable genome library V2.0 | Druggable genes | siRNA | log2 median | Complex criteria | | GR00143-A | 1459 | | CSNK2A2 | CSNK2A2 s1 | sp | none | | no | | tau phosphorylation | High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. | Azorsa et al. | 2010 | 20067632 | Cell line | H4 overexpressing 4RON tau | Total tau and 12E8 tau protein expression | Fluorescence | Validated human kinase siRNA Set 2.0 | Kinases | siRNA | p-value | Complex criteria | | GR00143-A | 1459 | | CSNK2A2 | CSNK2A2 s2 | sp | none | | no | | tau phosphorylation | High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. | Azorsa et al. | 2010 | 20067632 | Cell line | H4 overexpressing 4RON tau | Total tau and 12E8 tau protein expression | Fluorescence | Validated human kinase siRNA Set 2.0 | Kinases | siRNA | p-value | Complex criteria | | GR00149-A-1 | 1459 | 1459 | CSNK2A2 | 181 | -31.34 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1459 | 1459 | CSNK2A2 | 181 | -45.19 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1459 | 1459 | CSNK2A2 | 183 | 42.56 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1459 | 1459 | CSNK2A2 | 183 | -1.65 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1459 | 1459 | CSNK2A2 | 103393 | -13.91 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1459 | 1459 | CSNK2A2 | 103393 | 12.6 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00151-A-1 | 1459 | ENSG00000070770 | CSNK2A2 | np | 0.268 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. | Słabicki et al. | 2010 | 20613862 | Cell line | HeLa | (HR-DSBR) DR-GFP reporter | Flow cytometry | Custom-made | Genome-wide | esiRNA | Z-score | < -2 OR > 2 | | GR00155-A | 1459 | 1459 | CSNK2A2 | CSNK2A2_1, CSNK2A2_2, CSNK2A2_3 | np | none | | no | | Aryl hydrocarbon receptor (AhR) transduction pathway regulation | RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity. | Gilot et al. | 2011 | 21479225 | Cell line | MCF-7 | TCDD-induced CYP1A1-related EROD activity and cell viability | Fluorescence and methylene blue | MISSION siRNA Human Kinase Panel library | Kinases | siRNA | Z-score | Top 150 for > | | GR00173-A | 1459 | NM_001896 | CSNK2A2 | np | 62.7 | Decreased viability | | no | increased number of apoptotic cells | Rhabdomyosarcoma cell growth | Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. | Hu et al. | 2009 | 19887553 | Cell line | RH30 | Viability | Fluorescence | siRNA libraries (V2.0) | Kinases and phosphatases | siRNA | Percentage growth inhibition | np | | GR00173-A | 1459 | NM_001896 | CSNK2A2 | np | 35.3 | Decreased viability | | no | | Rhabdomyosarcoma cell growth | Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. | Hu et al. | 2009 | 19887553 | Cell line | RH30 | Viability | Fluorescence | siRNA libraries (V2.0) | Kinases and phosphatases | siRNA | Percentage growth inhibition | np | | GR00180-A-1 | 1459 | 1459 | CSNK2A2 | PL-50001 | 0.881 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00184-A-1 | 1459 | NM_001896 | CSNK2A2 | M-004752-00 | -1.08690347070909 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00193-A-1 | 1459 | 1459 | CSNK2A2 | CSNK2A2 | 0.291918967261746 | Decreased substrate adherent cell growth | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (1) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | EBC1 | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00193-A-2 | 1459 | 1459 | CSNK2A2 | CSNK2A2 | 1.05193951347797 | none | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (2) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | KELLY | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00193-A-3 | 1459 | 1459 | CSNK2A2 | CSNK2A2 | 0.74509926310233 | Decreased substrate adherent cell growth | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (3) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | SKNAS | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00193-A-4 | 1459 | 1459 | CSNK2A2 | CSNK2A2 | 0.935344817249376 | none | | no | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (4) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | NLF | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00196-A-1 | 1459 | ENSG00000070770 | | np | sp | Decreased viability of wild-type and TP53 knockout cells | | no | viability Z-score < -1.5 | TP53 interactions (1) | A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. | Krastev et al. | 2011 | 21642980 | Cell line | HCT116 ( wildtype and TP53 knockout) | TP53 protein expression and viability | Fluorescence | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00197-A-1 | 1459 | 1459 | CSNK2A2 | M-004752-00 | -1.715903221 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00209-A-1 | 1459 | NM_001896 | CSNK2A2 | np | np | none | | yes | | Ribosome biogenesis (1) | A protein inventory of human ribosome biogenesis reveals an essential function of exportin 5 in 60S subunit export. | Wild et al. | 2010 | 21048991 | Cell line | HeLa | Rps2 protein expression | Fluorescence | np | Selected genes | siRNA | Average relative rank from > | > 0.2 | | GR00209-A-2 | 1459 | NM_001896 | CSNK2A2 | np | np | none | | yes | | Ribosome biogenesis (2) | A protein inventory of human ribosome biogenesis reveals an essential function of exportin 5 in 60S subunit export. | Wild et al. | 2010 | 21048991 | Cell line | HeLa | Enp1 protein expression | Fluorescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | | GR00209-A-3 | 1459 | NM_001896 | CSNK2A2 | np | np | none | | no | | Ribosome biogenesis (3) | A protein inventory of human ribosome biogenesis reveals an essential function of exportin 5 in 60S subunit export. | Wild et al. | 2010 | 21048991 | Cell line | HeLa | Rpl29 protein expression | Fluorescence | np | Selected genes | siRNA | Average relative rank from > | > 0.25 | | GR00210-A | 1459 | 1459 | CSNK2A2 | np | sp | Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, decreased FA abundance, increased peripheral FA formation, increased cell spreading | | no | clusters: MC2, DC6, CC5 | Focal adhesion formation | Multiparametric analysis of focal adhesion formation by RNAi-mediated gene knockdown. | Winograd-Katz et al. | 2009 | 19667130 | Cell line | HeLa | paxillin protein expression | Fluorescence | SMARTpool siARRAY siRNA Libraries | Kinases, phosphatases and selected genes | siRNA | Z-score | > 3.5 OR < -3.5 | | GR00221-A-1 | 1459 | | CSNK2A2 | TRCN0000000615 | -1.2 | Decreased viability | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 1459 | | CSNK2A2 | TRCN0000000613 | -0.71 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 1459 | | CSNK2A2 | TRCN0000000614 | -0.43 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 1459 | | CSNK2A2 | TRCN0000000611 | 0.83 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 1459 | | CSNK2A2 | TRCN0000000612 | 1.77 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 1459 | | CSNK2A2 | TRCN0000000611 | 0.19 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 1459 | | CSNK2A2 | TRCN0000000614 | 0.3 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 1459 | | CSNK2A2 | TRCN0000000612 | 0.66 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 1459 | | CSNK2A2 | TRCN0000000615 | -1.88 | Decreased viability | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 1459 | | CSNK2A2 | TRCN0000000613 | -0.68 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 1459 | | CSNK2A2 | TRCN0000000614 | -0.46 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 1459 | | CSNK2A2 | TRCN0000000615 | -0.4 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 1459 | | CSNK2A2 | TRCN0000000612 | 0.01 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 1459 | | CSNK2A2 | TRCN0000000613 | 0.23 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 1459 | | CSNK2A2 | TRCN0000000611 | 0.88 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 1459 | | CSNK2A2 | TRCN0000000615 | -2.16 | Decreased viability | | no | essential gene | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 1459 | | CSNK2A2 | TRCN0000000613 | -1.53 | Decreased viability | | no | essential gene | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 1459 | | CSNK2A2 | TRCN0000000611 | -0.59 | none | | no | essential gene | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 1459 | | CSNK2A2 | TRCN0000000614 | 0.42 | none | | no | essential gene | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 1459 | | CSNK2A2 | TRCN0000000612 | 0.79 | none | | no | essential gene | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00225-A | 1459 | | CSNK2A2 | CSNK2A2_A | -1.072655 | none | 10nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | GR00225-A | 1459 | | CSNK2A2 | CSNK2A2_B | -0.603668 | none | 10nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | GR00225-A | 1459 | | CSNK2A2 | CSNK2A2_A | -0.074341 | none | 5nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | GR00225-A | 1459 | | CSNK2A2 | CSNK2A2_B | -0.265232 | none | 5nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | | 1459 | NM_001896 | CSNK2A2 | np | 0.841908 | none | | no | | | | | | | | | | | | | | | | | GR00230-A-1 | 1459 | NM_001896 | CSNK2A2 | TRCN0000000615 | 3.6 | Increased cell viability after pRB stimulation | | yes | | pRB-induced cell cycle regulation (1) | A kinase shRNA screen links LATS2 and the pRB tumor suppressor. | Tschöp et al. | 2011 | 21498571 | Cell line | SaOS2-TR-pRB | Cell number and viability | Colorimetrics | Lentiviral shRNA library | Kinases | shRNA | SD from the trendline | > 3.0 OR < -3.0 for > | | GR00231-A | 1459 | NM_001896 | CSNK2A2 | M-004752-00 | -1.554 | none | | yes | | Cell proliferation | Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. | Zhang et al. | 2011 | 21765947 | Cell line | HeLa | Viability | Electrical impedance | Human siARRAY - Protein Kinase and Cell Cycle libraries | Kinases and selected genes | siRNA | Z-score | < -1.96 OR > 1.96 | Additional information about cell titer blue cell viability screen | GR00234-A-1 | 1459 | NM_001896 | CSNK2A2 | np | sp | none | | no | | Hepatitis C virus (HCV) infection (1) | EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. | Lupberger et al. | 2011 | 21516087 | Cell line | Huh7 | Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) protein expression | Luminescence | Human Kinase RNAi Set V2.0 | Kinases | siRNA | Complex, sp | Complex criteria | | GR00236-A-1 | 1459 | 1459 | CSNK2A2 | M-004752-00 | 0.624244805054073 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00240-S-1 | 1459 | NM_001896 | CSNK2A2 | M-004752-00 | 8.33 | Decreased viability | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 1459 | NM_001896 | CSNK2A2 | M-004752-00 | np | none | | no | Z-score 3.727; viability Z-score > 4 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00242-A-1 | 1459 | NM_001896 | CSNK2A2 | np | sp | none | | no | | Selective autophagy regulation (1) | Image-based genome-wide siRNA screen identifies selective autophagy factors. | Orvedahl et al. | 2011 | 22020285 | Cell line | HeLa/GFP-LC3 | Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression | Fluorescence | siGenome | Genome-wide | siRNA | Z-score | Complex criteria | | GR00243-A | 1459 | 1459 | CSNK2A2 | 181, 183, 103306 | np | none | | no | | Cdk9 T-loop phosphorylation | Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway. | Ramakrishnan and Rice | 2012 | 21448926 | Cell line | HeLa | Cdk9 T-loop phosphorylation and beta-Actin protein expression | Fluorescence | np | Kinases | siRNA | np | > | | GR00247-A-1 | 1459 | | CSNK2A2 | np | sp | none | | | rank: 9801 | Regulation of FOXO1 nuclear localization (1) | Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. | Senapedis et al. | 2011 | 21460183 | Cell line | U2OS | EGFP-FOXO1a protein expression and DNA content | Fluorescence | Human Genome library | Genome-wide | siRNA | Complex, sp | Complex criteria | | GR00248-A | 1459 | NM_001896 | CSNK2A2 | CSNK2A2_siRNA1 | 0.942 | none | | | gene: decreased replication | Human cytomegalovirus (HCMV) strain AD169 replication | Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. | Terry et al. | 2012 | 22315427 | Cell line | MRC5 | Human cytomegalovirus (HCMV) IE1 protein expression | Fluorescence | Mission siRNA Human Kinase Panel | Kinases | siRNA | Z-score | > | | GR00248-A | 1459 | NM_001896 | CSNK2A2 | CSNK2A2_siRNA2 | -6.541 | Decreased human cytomegalovirus (HCMV) strain AD169 replication | | | gene: decreased replication | Human cytomegalovirus (HCMV) strain AD169 replication | Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. | Terry et al. | 2012 | 22315427 | Cell line | MRC5 | Human cytomegalovirus (HCMV) IE1 protein expression | Fluorescence | Mission siRNA Human Kinase Panel | Kinases | siRNA | Z-score | > | | GR00248-A | 1459 | NM_001896 | CSNK2A2 | CSNK2A2_siRNA3 | -4.789 | Decreased human cytomegalovirus (HCMV) strain AD169 replication | | | gene: decreased replication | Human cytomegalovirus (HCMV) strain AD169 replication | Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. | Terry et al. | 2012 | 22315427 | Cell line | MRC5 | Human cytomegalovirus (HCMV) IE1 protein expression | Fluorescence | Mission siRNA Human Kinase Panel | Kinases | siRNA | Z-score | > | | GR00249-S | 1459 | 1459 | CSNK2A2 | J-004752-05 | 1.86375 | Increased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 81.30 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1459 | 1459 | CSNK2A2 | M-004752-00 | -1.08506 | none | | no | number of cells compared to control (%): 77.08 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1459 | 1459 | CSNK2A2 | s3639 | 0.43548 | none | | no | number of cells compared to control (%): 94.76 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1459 | 1459 | CSNK2A2 | s3640 | -0.17116 | none | | no | number of cells compared to control (%): 74.91 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1459 | 1459 | CSNK2A2 | s3641 | 2.03193 | Increased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 73.07 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00250-A-1 | 1459 | 1459 | CSNK2A2 | M-004752-00 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 1459 | 1459 | CSNK2A2 | D-004752-01 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 1459 | 1459 | CSNK2A2 | D-004752-02 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 1459 | 1459 | CSNK2A2 | D-004752-03 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 1459 | 1459 | CSNK2A2 | D-004752-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-3 | 1459 | 1459 | CSNK2A2 | D-004752-01 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 1459 | 1459 | CSNK2A2 | D-004752-02 | sp | none | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 1459 | 1459 | CSNK2A2 | D-004752-03 | sp | none | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 1459 | 1459 | CSNK2A2 | D-004752-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00253-A | 1459 | NM_001896 | CSNK2A2 | np | -0.189 | none | | | | hepcidin regulation | Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. | Mleczko-Sanecka et al. | 2014 | 24385536 | Cell line | Huh7 | hepcidin::fluc mRNA expression | Luminescence | siGenome siARRAY SMARTpool | Genome-wide | siRNA | Z-score | > | Cutoff < | GR00255-A-1 | 1459 | 1459 | CSNK2A2 | TRCN0000000611, TRCN0000000612, TRCN0000000613, TRCN0000000614, TRCN0000000615 | -0.029514928 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 1459 | 1459 | CSNK2A2 | TRCN0000000611, TRCN0000000612, TRCN0000000613, TRCN0000000614, TRCN0000000615 | -0.256532835 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 1459 | 1459 | CSNK2A2 | TRCN0000000611, TRCN0000000612, TRCN0000000613, TRCN0000000614, TRCN0000000615 | -0.673170247 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 1459 | 1459 | CSNK2A2 | TRCN0000000611, TRCN0000000612, TRCN0000000613, TRCN0000000614, TRCN0000000615 | -0.766056639 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 1459 | 1459 | CSNK2A2 | TRCN0000000611, TRCN0000000612, TRCN0000000613, TRCN0000000614, TRCN0000000615 | 0.220063927 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00256-A | 1459 | NM_001896 | DAPK2 | np | sp | none | | | | Kinase-mediated spindle orientation | ABL1 regulates spindle orientation in adherent cells and mammalian skin. | Matsumara et al. | 2012 | 22252550 | Cell line | HeLa | beta-tubulin protein expression and DNA content | Fluorescence | Silencer Kinase siRNA library (AM80010V3) | Kinases | siRNA | Complex, sp | Complex criteria | HeLa cells stably expressing GFP-H2B (HeLa-GH2B) used. Additional information about secondary screens. | GR00293-A | 1459 | | CSNK2A2 | np | 1.082 | none | | | | Combinatorial effect with paclitaxel | Mechanisms Promoting Escape from Mitotic Stress−Induced Tumor Cell Death | Sinnott et al. | 2014 | 24860162 | Cell line | HCC366 | Viability | Luminescence | Thermo-Fisher | Genome-wide | siRNA | Z-score | < -2.5 | Final hits according to the author are indicated in the comment. | GR00300-A | 1459 | | CSNK2A2 | TRCN0000197008, TRCN0000196745, TRCN0000194896, TRCN0000000613, TRCN0000000612, TRCN0000000615, TRCN0000000614, TRCN0000000611, TRCN0000196663 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00303-A | 1459 | NM_001896 | CSNK2A2 | np | -0.51 | none | | | | Clear cell renal cell carcinoma (ccRCC) survival regulation | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Gerlinger et al. | 2012 | 22362593 | Cell line | VHL-deficient RCC4 | Proliferation and Viability | Fluorescence | np | Genome-wide | siRNA | Z-score | < | In the phenotype data duplicates were in the original document, which have been removed. | GR00310-A-1 | 1459 | 1459 | CSNK2A2 | np | -1.23 | none | | | | Sindbis virus (SINV) infection (1) | Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry | Ooi et al. | 2013 | 24367265 | Cell line | U2OS | Sindbis virus (SINV) reporter | Luminescence | Ambion Silencer V3 | Genome-wide | siRNA | Z-score | < -3 OR > 2 | | | 1459 | 1459 | CSNK2A2 | np | 80 | Decreased NF-kappaB reporter expression | | | 91.6% viability; included in validation screen | | | | | | | | | | | | | | | | GR00313-A | 1459 | NM_001896 | CSNK2A2 | np | 0.31 | none | | | | TNF-alpha pathway regulation | A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. | Nickles et al. | 2012 | 22733992 | Cell line | HEK293T | NFkappaB pathway reporter | Luminescence | Qiagen | Genome-wide | siRNA | Z-score | < | Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. | GR00318-A | 1459 | 1459 | CSNK2A2 | np | 1.464 | none | | | siRNA set: kinase | Huntingtin toxicity | A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease | Miller et al. | 2012 | 23209424 | Cell line | HEK293T | Caspase 3/7 activity | Fluorescence | Dharmacon | Selected genes | siRNA | Sum of normalized caspase 3/7 activity mean and standard error | < 0.683 | HEK293T cells were cotransfected with mutant Huntingtin fused to GFP (Htt1-558141Q-GFP). | GR00327-A | 1459 | 1459 | GCAT | CLL-H-011136 | -0.6922079808578159 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1459 | 1459 | GCAT | CLL-H-011132 | 1.3238042907401342 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1459 | 1459 | GCAT | CLL-H-011135 | 0.4941308479868156 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1459 | 1459 | GCAT | CLL-H-011134 | 0.33727037550697436 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1459 | 1459 | GCAT | CLL-H-011133 | -0.8597916541087841 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1459 | 1459 | GCAT | CLL-H-011137 | -1.2703394829211672 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00342-S-1 | 1459 | | CSNK2A2 | M-004752-00 | -1.1714965818695215 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (1) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 1 (MSC1a) | GR00342-S-2 | 1459 | | CSNK2A2 | M-004752-00 | -1.3784754708285953 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (2) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 2 (MSC1b) | GR00342-S-3 | 1459 | | CSNK2A2 | M-004752-00 | -1.0886210599872694 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (3) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 2, MSC preparation 1 (MSC2) | GR00343-S | 1459 | 1459 | CSNK2A2 | TRCN0000000615 | 0.15999999999999837 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 1459 | 1459 | CSNK2A2 | TRCN0000000611 | 0.20500000000000007 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 1459 | 1459 | CSNK2A2 | TRCN0000000613 | -1.5999999999999996 | shRNA abundance <= 50% | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 1459 | 1459 | CSNK2A2 | TRCN0000000614 | 0.5600000000000005 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00356-A-1 | 1459 | NM_001896 | CSNK2A2 | np | 0.49 | none | | | | Clathrin-mediated endocytosis | Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. | Pelkmans et al. | 2005 | 15889048 | Cell line | HeLa | Vesicular stomatitis virus (VSV) infection (rVSV–GFP expression) | Fluorescence | Ambion | Kinases | siRNA | Relative infection index (RII) | < | The cutoff was < 0.4 OR > 2.5 if the gene also scored in the additional screen "Caveolin- and lipid raft-mediated endocytosis" using simian virus 40 (SV40). | GR00356-A-2 | 1459 | NM_001896 | CSNK2A2 | np | 0.5974745767005919 | none | | | | Caveolin- and lipid raft-mediated endocytosis | Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. | Pelkmans et al. | 2005 | 15889048 | Cell line | HeLa | Simian virus 40 (SV40) infection (SV40 large T-antigen expression) | Fluorescence | Ambion | Kinases | siRNA | Relative infection index (RII) | < | The cutoff was < 0.4 OR > 2.5 if the gene also scored in the additional screen "Clathrin-mediated endocytosis" using vesicular stomatitis virus (VSV). | GR00356-A-3 | 1459 | NM_001896 | CSNK2A2 | np | np | none | | | | Endocytosis regulation | Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. | Pelkmans et al. | 2005 | 15889048 | Cell line | HeLa | Transferrin (Tfn) uptake and trafficking | Fluorescence | Ambion | Kinases | siRNA | np | np | | GR00363-A | 1459 | 1459 | CSNK2A2 | SI03110737, esi1126, 181, SI00029666, 183, 103306, SI00605409, SI00605416 | sp | Increased transferrin (TF) endocytosis | | | strong | Endocytosis regulation | Systems survey of endocytosis by multiparametric image analysis. | Collinet et al. | 2010 | 20190736 | Cell line | HeLa | Transferrin (TF) and epidermal growth factor (EGF) subcellular localisation, DNA content | Fluorescence | Ambion, Qiagen and esiRNA library (Kittler et al.) | Genome-wide | siRNA | Complex, sp | Complex criteria | Two hit categories: "strong" (maximum of Prob Chi2, Prob Chi2 EGF, Prob Chi2 Tfn > 0.95) and "weak but specific" (maximum of Prob Chi2, Prob Chi2 EGF, Prob Chi2 Tfn < 0.95 but Phenoscore > 0.95). Additional information about secondary screens with kinase and phospatase libraries. | | 1459 | 1459 | CSNK2A2 | | 0.009999999999999995 | none | | | | | | | | | | | | | | | | | | | GR00371-A-1 | 1459 | 1459 | CSNK2A2 | | 0.690141930428 | none | | | Dharmacon | Nanog expression in absence of bFGF and TGFbeta | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-2 | 1459 | CSNK2A2 | 1459 | | 0.133065252266 | none | | | Dharmacon | Nanog expression in presence of TGFbeta inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-3 | 1459 | 1459 | CSNK2A2 | | 0.415072136528 | none | | | Dharmacon | Nanog expression in presence of MEK inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-4 | 1459 | 1459 | CSNK2A2 | | 0.722142666521 | none | | | Dharmacon | Nanog expression in presence of PI3K inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-5 | 1459 | 1459 | CSNK2A2 | | 1.36698925063 | Increased Nanog expression | | | Dharmacon | Nanog expression in presence of retinoic acid | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00376-A-1 | 1459 | 1459 | CSNK2A2 | | 0.221476159 | none | | | | Mitigators of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID | GR00376-A-2 | 1459 | 1459 | CSNK2A2 | | 0.309663642 | none | | | | Sensitizers of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID | GR00378-A | 1459 | | CSNK2A2 | | -1.442821865 | none | | | | Poliovirus vaccine production | Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game | van der Sanden et al. | 2015 | 26581994 | Cell line | HEp-2C | Infection with Attenuated Poliovirus | ELISA | Dharmacon | Genome-wide | siRNA | Z-score | > | For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol | | 1459 | NM_001896 | CSNK2A2 | | 32.565 | none | | | | | | | | | | | | | | | | | | | GR00386-A-1 | 1459 | 1459 | CSNK2A2 | | 85.9443516631682 | none | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 1459 | 1459 | CSNK2A2 | | 41.6 | none | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |